Estelle Méroc1, Janeri Fröberg2, Timea Almasi3, Brita Askeland Winje4, Alejandro Orrico-Sánchez5, Anneke Steens4, Scott A McDonald6, Kaatje Bollaerts7, Mirjam J Knol6. 1. P95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001, Leuven, Belgium. estelle.meroc@p-95.com. 2. Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Laboratory of Medical Immunology, Section Paediatric Infectious Diseases, Geert Grooteplein 21, 6525 EZ, Nijmegen, the Netherlands. 3. Syreon Research Institute, Mexikoi str. 65/A, Budapest, 1142, Hungary. 4. Department of Infection Control and Vaccine, Norwegian Institute of Public Health, PO Box 222, Skøyen, 0213, Oslo, Norway. 5. Vaccines Research Unit, FISABIO (the Valencia Foundation for the Promotion of Health and Biomedical Research), Av. Catalunya, 21, 46020, Valencia, Spain. 6. Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA, Bilthoven, the Netherlands. 7. P95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001, Leuven, Belgium.
Abstract
BACKGROUND: To guide decision-making on immunisation programmes for ageing adults in Europe, one of the aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia. METHODS: We conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY), quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-reviewed publications published between 2009 and 2019. RESULTS: Morbidity and mortality data were generally available for all five diseases, while summary BoD estimates were mostly lacking. Available data were not always stratified by age and risk group, which is especially important when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC. CONCLUSION: This study provides an exhaustive overview of the available data sources and data gaps for the estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD studies and contribute to calculation of (P)VPDs BoD.
BACKGROUND: To guide decision-making on immunisation programmes for ageing adults in Europe, one of the aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia. METHODS: We conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY), quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-reviewed publications published between 2009 and 2019. RESULTS: Morbidity and mortality data were generally available for all five diseases, while summary BoD estimates were mostly lacking. Available data were not always stratified by age and risk group, which is especially important when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC. CONCLUSION: This study provides an exhaustive overview of the available data sources and data gaps for the estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD studies and contribute to calculation of (P)VPDs BoD.
Entities:
Keywords:
Burden of disease; Elderly; Infectious disease; Public health; Vaccine
Authors: M A de Wit; M P Koopmans; L M Kortbeek; W J Wannet; J Vinjé; F van Leusden; A I Bartelds; Y T van Duynhoven Journal: Am J Epidemiol Date: 2001-10-01 Impact factor: 4.897
Authors: Alies van Lier; Albert Jan van Hoek; Wim Opstelten; Hein J Boot; Hester E de Melker Journal: BMC Health Serv Res Date: 2010-08-13 Impact factor: 2.655
Authors: Clarence C Tam; Laura C Rodrigues; Laura Viviani; Julie P Dodds; Meirion R Evans; Paul R Hunter; Jim J Gray; Louise H Letley; Greta Rait; David S Tompkins; Sarah J O'Brien Journal: Gut Date: 2011-06-27 Impact factor: 23.059